Clinical Trials · NCT04003467
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Entera Bio Ltd.
- Enrollment
- 161
- Start date
- Jun 2019
- Locations
- 4 sites, Israel
- Primary endpoint
- Mean % change in P1NP from baseline after 3 months of treatment